ChemoCentryx publishes findings of role of CCR2 in kidney glomerulus
ChemoCentryx (CCXI) announced the peer-reviewed publication of positive results from in vivo studies examining the efficacy of inhibiting the chemokine receptor known as CCR2 in the treatment of focal segmental glomerulosclerosis, a debilitating chronic kidney disorder with no approved treatment option.
Data presented in the publication show that blocking CCR2 provides rapid and sustained renal protection in two well-established models of FSGS, as measured by reduction in proteinuria and improvement in multiple histological parameters.
The findings were published in the journal PLOS ONE under the title “CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis.”
Key findings from the study include: In two murine FSGS models, CCR2 inhibition markedly reduced proteinuria and improved renal function, both as a single agent and in combination with renin-angiotensin-aldosterone system blockade; The combination of CCR2 inhibition and RAAS blockade was as effective as the combination of endothelin receptor inhibition and RAAS blockade; and Improvements in renal function observed with CCR2 inhibition were associated with encouraging histological changes, as assessed by decreased glomerular sclerosis, mesangial expansion and tubular collapse, including increased podocyte density.
CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis.
CCXI is down 31 cents to $14.68.
To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.
This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.